NAMSA Expands Minneapolis Preclinical Laboratory to Meet Industry Demand for MedTech Research and Development Solutions

MINNEAPOLIS--(BUSINESS WIRE)--NAMSA, the world’s leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, announced today the expansion of its Minneapolis preclinical research laboratory. This expansion will add 55,000 sq. ft. to the current 130,000 sq. ft. preclinical campus in Minneapolis.

NAMSA, through its preclinical, interventional and surgical research services, provides medical device Sponsors a broad range of laboratory models and analysis tools, including state-of-the-art surgical instrumentation and catheterization labs, imaging capabilities and fully equipped surgical suites. With this expansion, the organization will increase capacity for early-stage feasibility studies and complex R&D investigations, while also adding additional surgical suites and catheterization laboratories.

“We are excited to announce the news of our expanded laboratory capacity at a time when there is an industry-wide challenge of increased lead-times for preclinical services and laboratory capacity,” commented Christophe Berthoux, NAMSA CEO. “With competitor-reported timelines of up to nine months for new preclinical projects, NAMSA is pleased to readily assist medical device innovators with the ability to conduct timely, high-quality safety and performance evaluations for early-stage R&D efforts through this expansion and increased capacity,” Berthoux concluded.

NAMSA’s Minneapolis preclinical laboratory expansion will occur in two stages with completion slated for April 2022 and December 2022, respectively.

Complimentary Consultations
NAMSA invites you to learn more about our preclinical capabilities, as well as our integrated preclinical-to-clinical solution for complex medical device development programs. Get in touch for a 30-minute complimentary consultation today: https://namsa.com/locations-contact/.

About NAMSA
Helping medical device Sponsors improve healthcare since 1967, NAMSA is the world’s leading MedTech Contract Research Organization (CRO) offering global end-to-end development services. Driven by its global regulatory expertise and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development, offering only the most proven solutions to move clients’ products through the development lifecycle efficiently and cost-effectively. From medical device testing; regulatory, reimbursement and quality consulting; and clinical research services, NAMSA is the industry’s premier, trusted partner for successful development and commercialization outcomes. Web: namsa.com